• refractory classic Hodgkin lymphoma (R/R cHL)
• R/R cHL - second line or more (L2) 1
• colorectal cancer (CRC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus cometinib
• pembrolizumab based treatment
• pembrolizumab alone
• Immune checkpoint association
• durvalumab plus tremelimumab

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs non active control
• vs BSC
• vs VEGF(R) inhibitor
• vs regorafenib

  All patients Age < 65y (younger) Age > 65y Age > 75y (older) Asian type BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male PD-L1 < 1% PD-L1 > 1% RAS mutant RAS wild type

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

colorectal cancer (CRC), immune chekpoint inhibitors vs. BSC, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;